A treatment for tardive dyskinesia and some other extrapyramidal symptoms

Journal of Clinical Psychopharmacology

Volumn 17, Issue 3, 1997, Pages 190-193

  Cowen, Murray A ^a   Green, Maurice ^a   Bertollo, David N ^a   Abbott, Karl ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMANTADINE; ANTIPARKINSON AGENT; BENZATROPINE; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; DIAZEPAM; FLUPHENAZINE DECANOATE; HALOPERIDOL; IMIPRAMINE; NEUROLEPTIC AGENT; PERPHENAZINE; PHENYTOIN; PSYCHOTROPIC AGENT; THIAMINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; AGED; ARTICLE; CEREBRAL PALSY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMENTIA; DOUBLE BLIND PROCEDURE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FEVER; HOSPITALIZATION; HUMAN; MALAISE; MALE; MENTAL PATIENT; NEUROLOGIC EXAMINATION; PARKINSONISM; PRIORITY JOURNAL; RASH; SCHIZOIDISM; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ACETAZOLAMIDE; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; THIAMINE;

EID: 0030989608     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199706000-00009     Document Type: Article

References (29)

1. Van Kammen D, Marder S. Dopamine receptor antagonists. In: Kaplan H, Sadock B, eds. Comprehensive textbook of psychiatry. 6th ed. Baltimore: Williams & Wilkins, 1995:1987-2022.
2. Cowen MA, Bagchi SP, Green M. The therapeutic effects of acetazolamide plus thiamine (A + T) on tardive dyskinesia correlate with a significant reduction in urine tryptamine [abstract]. Biol Psychiatry 1989;25:74A.
3. Jackson E. Diuretics. In: Hardman J, Limbird L, Molinoff P, Ruddon R, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw Hill, 1995:694-5.
4. Griggs RC, Engle WK, Resnik JS. Acetazolamide treatment of hyperkalemic periodic paralysis. Ann Intern Med 1970;73:39-48.
5. McArdle B. Adynamia episodica hereditaria and its treatment. Brain 1962;85:121-48.
6. Merlis S. Diamox, a carbonic anhydrase inhibitor. Neurology 1954;4:863-8.
7. Gotz F, Gimes L, Hubler J, Temes G, Frang D. Induced precipitation of calcium-oxalate crystals and its prevention in laboratory animals. Int Urol Nephrol 1986;18:363-8.
8. Tawil R, Moxley RT III, Griggs RC. Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology 1993;43:1105-6.
9. Levkovitch Y, Kronenberg J, Zvyagelski M, Gaoni B, Gadoth N. Clozapine for tardive dyskinesia in adolescents. Brain Dev 1995; 17:213-5.
10. Tamminga C, Thaker G, Moran M, Kakigi T, Gao X. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55[suppl B]:102-6.
11. Bennett JP Jr, Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994;9:409-14.
12. Dabiri LM, Pasta D, Darby JK, Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia Am J Psychiatry 1994;151:925-6.
13. Egan MF, Hyde TM, Albers GW, Elkashef A, Alexander RC, Reeve A, Blum, A, Saenz RE, Wyatt RJ. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992;149:773-7.
14. Physicians' desk reference. 49th ed. Montvale, NJ: Medical Economics Data Production Company, 1995:1255-6.
15. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education and Welfare, 1976:76-338.
16. Simpson G, Angus J. A rating scale for extrapyramidal effects. Acta Psychiatr Scand Suppl 1970;212:11-9.
17. Bartko J, Carpenter W. On the methods and theory of reliability. J Nerv Ment Dis 1976;5:307-17.
18. Afifi A, Azen S. Statistical analysis: a computer oriented approach. New York: Academic Press, 1972:212-4.
19. SAS Institute Inc. SAS/STAT user's guide, version 6. 4th ed., vol 2. Cary, NC: SAS Institute Inc., 1989:891-996.
20. Schnell RC. Enhancement of the chlorpromazine-induced suppression of the conditioned avoidance response by carbonic anhydrase inhibition. Neuropharmacology 1974;13:847-50.
21. Inoue H, Hazama H, Hamazoe K, Ichikawa M, Omura F, Fukuma E, Inoue K, Umezawa Y. Antipsychotic and prophylactic effects of acetazolamide (Diamox) on atypical psychosis. Folia Psychiatr Neurol Jpn 1984;38:425-36.
22. Spatz M. Attenuated blood-brain barrier. In: Lajtha J, ed. Handbook of neurochemistry. 2nd ed., vol 7. New York: Plenum Press, 1984:501-43.
23. 2. Anesthesiology 1968;29:471-7.
24. Laux BE, Raichle ME. The effects of acetazolamide on cerebral blood flow and oxygen utilization in the rhesus monkey. J Clin Invest 1978;585-92.
25. Innes IR, Nickerson M. Norepinephrine, epinephrine and the sympathomimetic amines. In: Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics. 5th ed. New York: Macmillan, 1975:477-513.
26. Robinson BH, Oei J, Cheema-Dhadli S, Halpem ML. Regulation of citrate transport and pyruvate dehydrogenase in rat kidney cortex mitochondria by bicarbonate. J Biol Chem 1977;252: 5661-5.
27. Francois C. Ion transport and oxidative metabolism, III. Interaction of the sulfonamides with some non-heme iron flavoproteins of the respiratory chain. Arch Int Physiol Biochim Biophys 1972; 80:799-806.
28. Mayes PA. Metabolism of carbohydrate. In: Matrin DW Jr, Mayes PA, Rodwell VW, Granner DK, eds. Harper's review of biochemistry. 20th ed. Los Altos, CA: Lang Medical Publishers, 1985: 166-93.
29. Martin DW Jr. Water-soluble vitamins. In: Matrin DW Jr, Mayes PA, Rodwell VW, Granner DK, eds. Harper's review of biochemistry. 20th ed. Los Altos, CA: Lang Medical Publishers, 1985: 101-17.